Clinical distribution and drug resistance of Acinetobacter baumannii causing nosocomial infection

Objective:To determine the specimens source,infection distribution and drug resistance of Acinetobacter baumannii(ABA)isolated from our hospital from Jan.2008 to Dec.2012 and provide evidence for clinical prevention and treatment of it.Method:Bacterial cultivation,identification and susceptibility testing were performed by the microbiological routine methods.The specimens source and department distribution of 221 ABA had been summarized and analyzed retrospectively,resistance rates of 12 commonly used antimicrobial drug had be counted.Result:182 strains in a total of 221 A.baumannii strains were isolated from sputum accounting for82.4%,followed by pus,drainage incision,blood,and so on.The majority of ABA causing nosocomial infection was observed in ICU(51.5%),followed by respiratory medicine(24.4%),neurosurgery(19.9%)and other departments.Susceptibility results showed that ABA resistant to commonly used antibiotics increased year by year.Resistance rate of cefoperazone/sulbactam was the lowest,followed by imipenem,meropenem.ABA were highly resistant to penicillins,aminoglycosides,fluoroquinolones,aztreonam,piperacillin/tazobactam(90%),and showed multiple drug resistance.Conclusion:Concurrence of nosocomial infection caused by ABA increased year by year.It was highly resistant to common antimicrobials and demonstrated distinct multi-drug resistance.This should lead to clinical attention,especially in ICU and Respiratory Medicine.Improve treatment efficacy and reduce drug-resistant strains by strictly operating aseptic technique of invasive procedures and using antibiotics rational.